



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

30 April 2020
EMA/CHMP/227535/2020
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Cablivi caplacizumab

On 30 April 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Cablivi. The marketing authorisation holder for this medicinal product is Ablynx NV.

The CHMP adopted an extension to the existing indication as follows:²

Cablivi is indicated for the treatment of adults **and adolescents of 12 years of age and older weighing at least 40 kg** experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

² **New text in bold**

